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Many long-term mouse Th cell clones can be divided into two types, based on
the pattern of cytokines secreted in response to antigen or lectin stimulation . Thl
clones secrete IL-2, IFN-y, and lymphotoxin (LT),' whereas Th2 clones express IL-
4, IL-5, IL-6, and a gene ofunknown function, P600 (1-4) . Both types of clone se-
crete IL-3, granulocyte-macrophage CSF (GM-CSF), TNFa, preproenkephalin,
and several other induction-specific proteins. Thedifferences between Thl and Th2
cytokine synthesis patterns lead to markedly different functions (5-8) . Th2 clones
are normally betterB cell helpers (8, 9), whileThl clones, although they canprovide
B cell help in some circumstances (7, 10, 11), preferentially induce macrophage acti-
vation (12) and delayed-type hypersensitivity (DTH) (6) . Recent evidence (Street,
N. E., J . H. Schumacher, TA. T Fong, H . Bass, D . F Fiorentino, J. A. Leverah,
and T. R. Mosmann, manuscript in preparation) (13-15) suggests that other differen-
tiation states ofmouse Th cells exist, and that the Thl and Th2 phenotypes repre-
sent activated effector cells .
The existence ofthesetwomajortypesofTh cell mayexplain thewell-documented
separation ofimmune responses intoDTH or antibody production, which often ap-
pear to be mutually exclusive (16) . IfB cell helpandDTH arepredominantly medi-
ated by Th2 and Thl cells, respectively, this suggests that Thl and Th2 cells may
be mutually inhibitory (17, 18) . The Thl product IFN-y inhibits proliferation of
Th2 clones in vitro (19, 20), while an unknown product ofa Th2 clone may inhibit
the proliferation of Thl clones (21) . In addition to crossinhibition of proliferation,
we considered the possibility that inhibitors ofThl and Th2 effector function also
exist . Here, we report the preliminary characterization ofa cytokine produced by
Th2 clones that inhibits thesynthesis ofseveral cytokinesbyThl clones . This cytokine,
which we have called cytokine synthesis inhibitory factor (CSIF), has been distin-
guished from the other known Th2 cytokines .
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Materials and Methods
Mice.
￿
BALB/c, C57BL/6, and CBA/J mice were obtained from TheJackson Laboratory
(Bar Harbor, ME) and the Institute of Medical Research (SanJose, CA). Female mice 8-12
wk old were used in all experiments.
Cell Lines.
￿
Thl clones included: HDK-1, BALB/c anti-KLH (2); MD13-2, BALB/c anti-
CRBC (1); MD13-10, BALB/c anti-CRBC (1); GK15-1, CBA/J anti-CRBC (11); LB2-1,
C57BL/6 anti-CRBC (1); ML3-A-Cl-2-Ba, C57BL/6 anti-BALB/c; and ML3-A-C2-6-Nb,
C57BL/6 anti-BALB/c. Th2 clones included: D10.G4.1 (D10), AKR/J anti-conalbumin, ob-
tained from C. Janeway (Yale University, New Haven, CT) (22); CDC25 and CDC35, C3D2
anti-rabbit IgG, obtained from D. Parker (University of Massachusetts, Worcester, MA) (23);
D9, C57BL/6, obtained from G. Nabel (Harvard University, Boston, MA) (24); MB2-1,
C57BL/6 (1); and M411-2 and M411-6, BALB/c anti-CBA/J. The maintenance and stimula-
tion of antigen-specific T cell lines have been described previously (1, 2). The mouse T cell
line HT2 (25) was obtained from S. Strober (Stanford University, Stanford, CA) and the
WEHI 164.13 line (26) from M. Palladino (Genentech, South San Francisco, CA).
Media.
￿
Assay medium consisted of RPMI 1640 (J . R. Scientific Inc., Woodland, CA)
with 10 17o FCS (J. R. Scientific Inc.), 0.05 mM 2-ME (Sigma Chemical Co., St. Louis, MO),
and 20 mM Hepes (Gibco Laboratories, Grand Island, NY). T cell growth medium con-
sisted of assay medium containing 330 U/ml mouse rIL-2.
Antibodies.
￿
mAbs against IL-2 (S4B6), IL-5 (TRFK4 and TRFK5), and IFN-'Y (XMG1.2)
have been described previously (1, 2, 27). The anti-IL-3 mAbs 8F8.11 and 43D.11 (28), as
well as the anti-GM-CSF antibodies 22E9.11 and 35E10.11, were obtained fromJ. S. Abrams
(DNAX), the anti-IL-4 antibody I1B11 (29) was from W. E. Paul (National InstitutesofHealth,
Bethesda, MD), and the 6B4 anti-IL-6 antibody (30) fromJ. van Snick (Ludwig Cancer In-
stitute, Brussels, Belgium). The hamster anti-mouse T3 mAb 145-2CII (31) was obtained
fromJ. Bluestone (N. I. H.). Polyclonal rabbit IgG antibodies specific for transforming growth
factorS(TGFfl) were obtained from R & D Systems (Minneapolis, MN), and control rabbit
IgG antibodies were obtained from R. Coffman (DNAX).
T Cell Supernatants.
￿
Antigen-induced T cell supernatants were prepared by incubating
T cell clones (2 x 105 cells/ml) with irradiated APC (5 x 106 cells/ml) and antigen in assay
medium. Serum-free Con A-induced T cell supernatants were prepared by incubating T
cell clones (5 x 106 cells/ml) with Con A (5 Wg/ml; Sigma Chemical Co.) in RPMI 1640
lacking phenol red (Gibco Laboratories) and containing 0.05 mM 2-ME and 20 mM Hepes
for 24 h.
Cytokines.
￿
TGFa was obtained from R & D Systems. Purified mouse P40 (32) was gener-
ously provided by J. van Snick (Ludwig Cancer Institute). Purified mouse IL-5 (33) was
depleted ofknown Th2 cytokines and providedby R. Coffman, DNAX. Purified recombinant
mouse cytokines were provided by: M. Howard, DNAX(IL-4); R. Kastelein, DNAX(IL-4);
F. Lee, DNAX (IL-6 and IL-7); J. Schreurs, DNAX (IL-3 and GM-CSF); G. Zurawski,
DNAX(human IL-Ia); Schering Research, Bloomfield, NJ (IL-2 and IFN-y); and M. Pal-
ladino, Genentech (TNFa).
Cytokine Bioassays.
￿
The MTT assay (34), as modified (1), was used to measure IL-2, IL-4,
and LT/TNFa using mAbs to establish monospecificity for IL-2 and IL-4 assays (2, 26).
LT/TNFa was assayed on WEHI 164.13 cells essentially as described by Espevik and Nissen-
Meyer (26), except that 5 x 103 target cells/well were used, and the assay was carried out
in the presence ofsaturating (>2 ng/ml) amounts ofIFN-y. Units of activity were calculated
as described previously (1).
Cytokine ELISAs.
￿
Two-site sandwich ELISAs for IL-3, IL-5, and IFN-y were carried out
as described previously (2, 27, 28). The ELISA for GM-CSF was carried out essentially as
described for the IL-5 assay, using the mAbs 35E10 and 22E9. Intracellular IFN-y levels were
measured after lysing cells in 1% Triton X-100 (Sigma Chemical Co.) and removing nuclei
by centrifugation.
Column Chromatography.
￿
1-2 .5-liter batches of serum-free Con A-induced D10 superna-
tant were concentrated N10-fold using YM-5 membranes (Amicon Corp., Danvers, MA),
passed through a 5-ml mannose-conjugated agarose column (E-Y Laboratories, San Mateo,FIORENTINO ET AL.
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CA), then further concentrated another three- to fivefold, for a total concentration of30-50-
fold. This material was fractionated by HPLC on a hydroxylapatite-based support (Bio-Gel
HPHT, Bio-Rad Laboratories, Richmond, CA) and on a gel filtrationcolumn (TSK-G 3000
SW, 60-cm length; LKB Instruments, Gaithersburg, MD) as previously described (33). After
sequential chromatography on these two media, the fraction with CSIF activity is referred
to as partially purified CSIF (ppCSIF).
Antigens.
￿
Keyhole limpet hemocyanin was obtained from Pacific Bio-Marine Laborato-
ries, Inc. (Venice, CA) and used at a finalconcentration of 150 /Ag/ml. TNP-KLH (132 TNP
residues per 106 daltons protein) was used at 1 p,g/ml (35). Conalbumin (Sigma Chemical
Co.) was used at 100 Kg/ml. Chicken red blood cells were obtained from PMK farms(Vacaville,
CA) and used at 0.02% packed volume.
Anticytokine Affinity Columns.
￿
Six affinity columns were prepared by coupling the mAbs
XMG1.2 anti-IFN-y, 22E9.11 anti-GM-CSF, S4B6 anti-IL-2, 8F8.11 anti-IL-3, 11BIl anti-
IL-4, and TRFK5 anti-IL-5 to Affi-Gel 10 (Bio-Rad Laboratories). Each 1-2-ml column
contained -10-20 mg of coupled antibody.
CSIFAssay.
￿
Samples were diluted in 96-well flat-bottomed microtiter trays (Falcon Lab-
ware, Oxnard, CA) in a volume of 0.05 ml. Thl cells (5 x 104 cells/well), irradiated (2,500
rad) syngeneic spleen cells (5 x 105 cells/well), and antigen were added in a volume of 0.15
ml. 11BIl anti-IL-4 mAb (10,ug/ml) was added to the assay ifsamples were suspected ofcon-
taining IL-4. Levels of IFN-y and other cytokines in the 24-h supernatants were assayed.
Omission of either antigen or APC resulted in negligible cytokine synthesis. When initially
assayed, one batch of ppCSIF inhibited IFN-y production by -50% at a dilution of 1 :200
in an assay volume of0.2 ml, and so the standard unit (SU) was defined by assigning a value
of 1,000 SU/ml to this CSIF preparation. CSIF activity in unknown samples was quantitated
by comparing levels of inhibition of IFN-y synthesis by the unknown with that of the stan-
dard in each assay using a four-parameter curve-fitting program (Assay Zap; Biosoft, Cam-
bridge, UK). Means t SD of triplicate cultures were determined.
mRNA Measurement.
￿
Thl cells were stimulated with antigen plus APC that had been
depleted of erythrocytes by centrifugation over Ficoll (Histopaque; Sigma Chemical Co.).
At 8 and 12 h, aliquots of the cells were withdrawn and cytoplasmic RNA was isolated (36).
Dilutions ofRNA were bound to filters and hybridized with synthetic DNA probes that were
"P-labeled by fill-in synthesis of overlapping DNA oligonucleotides as described previously
(2). The DNA probes corresponded to bases 900-989 for IFN--Y (2) and 1262-1363 for y-actin
(37). Filters were exposed to x-ray film and the autoradiographs quantitated by laser den-
sitometry.
Results
Supernatantsfrom Th2 but not Thl Clones Inhibit Synthesis ofIFN--y by Thl Clones.
￿
Con
A-induced supernatants from seven Th2 clones all inhibited IFN-'r production by
HDK-1 cells (Fig. 1 A). This inhibitory activity was produced by D10 cells in re-
sponse to Con A, antigen plus APC, or antiT3 plus APC (Fig. 1 B). The inhibitory
activity appeared to be produced only by stimulated cells, since Con A-stimulated
CDC25 and CDC35cells produced 866 and 708 U/ml ofinhibitoryactivity, respec-
tively, whereas unstimulated cells produced <40 U/ml. We will call the factor respon-
sible for this activity CSIF
The decrease in IFN-'Y production could be due to a decrease in synthesis and/or
secretion. If a block in secretion was solely responsible for the reduced IFN-y super-
natant levels, then the intracellular levels of IFN-y should be greatly elevated in the
presence of CSIF When HDK-1 cells were stimulated with antigen plus APC, the
maximum extracellular IFN-y levels at 24 h were 250 and 1,100 ng/ml in the pres-
ence and absence of CSIF, respectively. The corresponding maximum intracellular
levels were 1.0 and 4.5 ng/ml.2084
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FIGURE 1.
￿
Th2 clones producean inhibitor ofIFN-ysynthesis by Thl cells. HDK-1 cells were
stimulated with antigen plus APC in the presence of supernatants from seven Con A-induced
Th2 clones (A)or from D10cellsinducedwith ConA, Ag plus APC, or antiT3 mAb(4.5 /+g/ml)
plus APC (B). IFN--y secretion is expressed as apercentage of thelevels produced in theabsence
of the Th2-derived inhibitor.
Four Con A-induced Thl supernatants were depleted of IFN--y and IL-2 (which
wouldinterfere with the CSIF assay) by passageover monoclonal anticytokine affinity
columns, and then tested forCSIF activity. TheseThl supernatants, even at adilu-
tion of 1:10, did not inhibit IFN-7 production (Fig. 2 A). The slightly increased
IFN--y levels in cultures treatedwith the highest concentration ofM264-37 superna-
FIGURE 2.
￿
Thl clones do notsecreteCSIF. Super-
natants from four Con A-induced Thl clones were
depleted of IL-2, IL-3, IFN-y, and GM-CSF, and
tested for CSIF activity using HDK-1 cells (A). In-
hibition by ppCSIF is shown for comparison. The
same sampleswere also tested in the presence of 14
U/ml ppCSIF(B). Theupperandlowerdashed lines
represent thelevels ofIFN-yin theabsence andpres-
ence of CSIF, respectively. All values are expressed
as a percentage of the IFN--y levels produced in the
absence of both ppCSIF and Thl supernatants.MORENTINO ET AL.
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tant could be accounted for by the residual IFN-y in this sample. Thus, Thl super-
natants either do not contain CSIF, or they contain both CSIF and an inhibitor
that masks its activity. This second possibility is ruled out by the demonstration
that IL-2- and IFN-y-depleted Thl supernatants did not counteract CSIF activity
(Fig. 2 B). Taken together, these experiments demonstrate that Th2 but not Thl
supernatants contain CSIF.
CSIF Inhibits Production ofSeveral Thl Cytokines.
￿
Since ppCSIFstillcontained GM-
CSF and IL-3, the levels ofthese cytokineswere furtherreduced byusinganticytokine
affinity columns before testing for CSIF's ability to inhibit the synthesis of several
otherThl Cytokines. Production ofIFN-y was consistently inhibited in allThl clones
tested (e.g., Table 1). The synthesis ofIL-2, LT/TNF, IL-3, and GM-CSF was in-
hibited in some cases but not others; e.g., IL-2 production was inhibited in HDK-1
cells but not in MD13-10 cells. When inhibition was observed, the extent ofmax-
imum inhibition varied between different clones and cytokines, ranging from -60
to >95To. Even for a single clone, different cytokines were maximally inhibited at
different concentrations ofCSIF In particular, thesynthesisofLT/TNFwas inhibited
by relatively low concentrations ofCSIF, but the extent ofmaximal inhibition was
much less than that of IFN-y.
CSIFInhibits Late but notEarly Cytokine Synthesis.
￿
Thekinetics ofinhibition ofcytokine
synthesis were examined for antigen-stimulated HDK-1 cells (Fig. 3). In general,
the synthesis ofall cytokines was not inhibited by CSIF at early times, e.g., before
8.5 h (before 6.5 h for IL-2). Twocytokines synthesized mainly at early times (GM-
CSF and LT/TNF) were inhibited slightly or not at all, whereas the synthesis of
cytokines produced mainly at later times (IFN-y and IL-3) was inhibited substan-
tially. Differences in the exact kinetics ofCSIF action and cytokine synthesis could
thus account for some of the variability of inhibition seen in Table I.
Inhibition of IFN-,y Synthesis Occurs at the mRNA Level.
￿
HDK-1 cells were stimu-
lated with antigen plus APC in the presence or absence ofppCSIF, and total cyto-
plasmic RNA was prepared from cells at8 and 12 h after stimulation. RNAsamples
were tested for IFN-,y and y-actin mRNA levels by dot-blot hybridization. IFN-y
TABLE I
Effect of CSIF on the Synthesis of Thl Cytokines
HDK-1 and MD13-10cells were stimulated with antigen plus APC in the presence
of varying dilutions of ppCSIF that had been depleted of GM-CSF and IL-3.
Cytokine levels in the 24-h supernatants are expressed as a percentage of the
amount produced in the absence of CSIF.
Cell line Cytokine 14 U/ml
Percent
CSIF
of control synthesis level
42 U/ml CSIF 125 U/ml CSIF
HDK-1 IFN-,y 47.6 t 0.8 29.1 t 1 .0 18.6 t 0.7
IL-2 71 .7 ± 2.3 59.6 t 3.9 40.4 t 6.1
LT/TNF 41 .9 t 1 .4 45.1 t 2.3 42.8 t 1 .1
IL-3 63.9 t 11 .4 52.6 t 6.8 38.4 t 1 .9
GM-CSF 86.9 t 8.5 79.1 t 7.8 66.8 t 9.3
MD13-10 IFN-,y 36.0 t 4.9 27 .5 t 3.4 23.2 t 2.6
IL-2 88.2 t 5.1 109.3 t 13 .3 96.0 t 16.4
IL-3 60.2 t 5.1 63.0 t 2.7 51.0 t 6.5
GM-CSF 109.9 t 13.0 119.9 t 7.4 97.6 t 19.22086
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FIGURE 3 .
￿
Kinetics of inhibition of cytokine synthesis by CSIF HDK-1 cells were stimulated
with antigen plus APC in the presence or absence of 100 U/ml ppCSIF that hadbeen depleted
of IL-3, IL-4, IL-5, and GM-CSF. Supernatants were collected at the indicated times and as-
sayed for cytokine levels .
mRNA levels were moderately reduced by CSIF at 8 h, and strongly reduced at
12 h over a range of 5-40 U/ml CSIF (Fig . 4) . In contrast, y-actin mRNA levels
were not significantly reduced by CSIF at either 8 or 12 h, and possibly showed a
slight enhancement at 12 h . The inhibition ofIFN-y protein levels in the 24-h super-
natants by CSIF was slightly less than the inhibition ofmRNA levels at 12 h .
Thl but not Th2 Clones Respond to CSIF .
￿
ppCSIF was tested on seven Thl clones
that were derived from three mouse strains andwere specific forparticulate antigens,
FIGURE 4 . CSIF reduces mRNA
levels for IFN-'Y but not actin . HDK-1
cells were stimulated with antigen plus
APC in the presence or absence of
ppCSIF. Cellswere harvested at 8and
12h for cytoplasmic mRNA isolation,
and supernatants were taken at 24 h
for IFN-.y protein determination .
mRNA levels were assessed by hybrid-
ization with synthetic DNA probes,
and protein wasmeasured by ELISA .
All values are expressed as a percentage
of levels produced in the absence of
CSIF.0
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FIGURE 5. Thl but not Th2
clones respond to CSIF. Seven
Thl clones werestimulated with
antigen plus APC in the pres-
ence ofdilutions ofppCSIF, and
IFN-,y secretion was measured
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soluble proteins, or alloantigens. IFN-,y synthesis by all seven clones was inhibited
by ppCSIF (Fig. 5 A). Since some ofthe Th2 cytokines may have been present in
the ppCSIF preparation, IL-3, IL-4, and IL-5 were depleted by passage over mAb
affinity columns. The resulting CSIF preparation did not suppress the production
ofIL-3, IL-4, or IL-5 by the Th2 clone D10 (Fig. 5 B). Two additional experiments
with D10 yielded similar results, and in other experiments (not shown), CSIF did
not inhibit the production of IL-5 by the Th2 clones MB2-1, CDC25, or CDC35,
nordid it inhibit IL-4 synthesis by MB2-1. Synthesis ofother cytokines in response
to antigen plus APC in these experiments was too low to reliably determine CSIF
effects. In general, we have not seen convincing inhibition ofthe production ofany
cytokine by Th2 cells responding to antigen plus APCs.
CSIFAction on Thl Cells May Be Indirect.
￿
CSIF inhibited IFN-'y synthesis in re-
sponse to antigen plus APC or antiT3 plus APC, but not IFN-,y synthesis stimu-
lated byanti-T3 bound to a polystyrene surface, or by Con A(Table II). Since only
the stimulations involving APC were inhibitable, CSIF may act indirectly on the2088
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TABLE II
CSIF Is Effective in Stimulations Involving APC
HDK-1 cells were stimulated with antigen plus APC, anti-T3 mAb (9 ug/ml) plus APC, anti-T3 bound to
96-well flat-bottomed trays, or Con A (5 Ag/ml), each in the presence or absence of CSIF-containing 1310
supernatant. Trays were coated with anti-T3 by incubating with 50 ug/ml anti-T3 mAb in 50 141 PBS for
1 h at 37°C, following which, the plates were extensively washed. IFN-1' levels in 24-h supernatants are ex-
pressed as a percentage of the amounts produced in the absence of CSIF, using the corresponding stimula-
tion condition.
Tcells, via a cell type in the APC population. CSIF acts mainly at later times (Fig.
3), consistent with the hypothesis that CSIF is first modified into, or induces a sec-
ondary factor that then inhibits IFN--y synthesis. Additional evidence for indirect
action was obtainedby varying the CSIF assay conditions. 10-fold changes in Tcell
and/or APC numbers did not affect the extent ofinhibition of IFN-y synthesis by
CSIFor the sensitivity ofdetectionofCSIF(data not shown). In contrast, saturating
amounts ofCSIF inhibited IFN-y synthesismore effectively(to 16% instead of35%
ofcontrol IFN-y amounts) ifthe assay volume were reduced twofold. Ifthe residual
IFN-y levels represent thecytokine secreted at early times before CSIF action, these
results are consistent with the inhibition of IFN--y synthesis being dependent on
a soluble factor produced in the assay. In this case, such a factor would accumulate
to effective concentrations more rapidly in a smaller assay volume.
CSIFDoes notDirectly Inhibit Thl Proliferation.
￿
Incontrast to itseffect on Thl cytokine
synthesis, CSIF had no measurable effect on the ability ofThl cells to proliferate
in response toIL-2. In thepresence ofexogenousIL-2 (500 ng/ml), antigen-stimulated
HDK-1 cells proliferated 5.2-fold by day 3, and 42.6-fold by day 6, as assessed by
cell counting. The corresponding proliferation values in the presence ofIL-2 plus
100 U/ml ppCSIF were 5.0-fold and 40.0-fold. Similar results (not shown) were ob-
tained using the MTT assay. However, in the absence of exogenous IL-2, ppCSIF
was sometimes able todecrease proliferationofHDK-1 cells when addedat the time
ofantigen stimulation (results not shown); presumably, this inhibition was indirect
and was a result ofCSIF's ability to reduce IL-2 production by HDK-1 cells (Table
I, Fig. 3).
Other Cytokines that Affect IFN--y Synthesis.
￿
In somebut not all experiments, exoge-
nous IL-4 and especially IL-2 increasedthe production ofIFN-ybyThl clones (data
not shown). SinceIL-2 was synthesized invariable amounts bystimulated Thl cells,
exogenous IL-2andIL-4mightonlybeeffective in experiments inwhichnonsaturating
amounts of endogenous IL-2 were synthesized. In the experiment shown in Fig.
6 A, anti-IL-2 antibody inhibited the production of IFN-y, indicating that normal
IFN--y synthesis was enhanced by IL-2 produced by theThl cells respondingto an-
Exp . Stimulation 5 U/ml CSIF
Percent of control
19 U/ml CSIF
IFN--y synthesis
74 U/ml CSIF 294 U/ml CSIF
1 Antigen plus spleen 72.6 f 12.8 29.1 t 3 .5 20 .5 t 6.6
Anti-T3 plus spleen 88.7 t 8.0 78.6 t 2 .8 68.5 t 2.6
Anti-T3 (coated) 95.7 t 6.7 103.3 f 6.7 94 .5 f 9.3
Con A 102.7 ± 4.2 95.4 ± 5 .3 94 .7 t 5.0
2 Antigen plus spleen 17 .5 t 5 .9 12.8 t 1 .6 8.2 ± 1 .8
Anti-T3 plus spleen 54.5 ± 3 .1 45 .6 t 6.0 42.0 t 7.2FIORENTINO ET AL .
￿
2089
FIGURE 6 .
￿
Effects of IL-2, IL-4, andTGR
S on IFN-y synthesis. HDK-1 cells were
stimulated with antigen plus APC with var-
ious combinations ofcytokinesand antibodies:
IL-2 (500 ng/ml), IL-4 (50 ng/ml),TGF-0 (10
ng/ml), ppCSIF (125 U/ml), 54136 anti-IL-2
(10 1&g/ml), rabbit antiTGR0 (50jig/ml), and
normal rabbit IgG (50 Kg/ml) (A and B).
Titrations ofthese reagents showed that these
levels were saturating . All cultures contained
111311 anti-IL-4 (10 pg/ml), except those in
which IL-2 or IL-4 was added (A) . All values
are expressed as a percentage of the IFN-y
levels produced in the absence ofppCSIF, an-
tibodies, and cytokines.
tigen plusAPC . When anti-IL-2 antibody was present, IL-4 enhanced IFN-y produc-
tion slightly, and excess IL-2 (overcoming the effect ofthe anti-IL-2 antibody) could
strongly enhance IFN-y levels . Although both IL-2 and IL-4 antagonized the effect
of CSIF by increasing the amount of IFN-y secreted, CSIF was still active in the
presence or absence of saturating amounts of IL-2 or IL-4 (Fig . 6 A) .
Partially purified antiTGFf3 antibodies slightly enhanced the synthesis ofIFN-y,
whereas exogenous TGF-0 slightly inhibited IFN-y production (Fig. 6 B) . These
results suggest that IFN-y synthesis can be inhibited by TGFf3, and that TGF-0
is produced in the assay under normal conditions . CSIF inhibited IFN-y produc-
tion in the presence or absence of TGF-0 or antiTGF0, showing that CSIF is not
TGF-i3 .
Partial Purification and Biochemical Characterization of CSIF .
￿
CSIF-containing D10
supernatants were chromatographed on two media . On both columns, CSIF ac-
tivity eluted in a single area. On the hydroxylapatite-based support, 95% of the ap-
plied activity was recovered ; also shown are the elution positions of other proteins
(Fig . 7 A) . On the gel filtration column, 63% of the applied activity eluted broadly,
with the fractions of high activity corresponding to apparent molecular masses of
27-50 kD (Fig . 7 B) . The width ofthe peak may be the result ofmicroheterogeneity
similar to that observed with other cytokines (e.g ., IL-5 ; [33]) . CSIF could be se-
quentially chromatographed on both columns in either order with no significant
alteration of relative mobility or activity yield (data not shown) . These results sug-
gest that CSIF may be a single entity, and we have not yet observed any evidence
for directly synergistic interactions ofCSIF with any other cytokine. ppCSIF (2,100 U
in 0.25 ml 10 mM phosphate buffer, pH 7.4) was carefully acidified to pH 2 with
HCl, allowed to stand for 1 h at room temperature, neutralized with 1 M Hepes
(sodium salt), and immediately assayed; <5% of the activity remained .
CSIFIs Distinctfrom Known Thl andTh2 Cytokines.
￿
Various blocking anticytokine
monoclonal and polyclonal antibodies were tested for the ability to inhibit CSIF ac-2090
￿
Th2-DERIVED INHIBITOR OF Thl CYTOKINE SYNTHESIS
FIGURE 7 .
￿
Column chromatography ofCSIFcontaining D10 supernatant . 10 ml of27-fold con-
centrated D10 supernatant applied to a Bio-Gel HPHT column in 10 mM sodium phosphate,
pH 7.4, 0.12mM CaC12, 0.01% Tween-20 at a flow rate of0.5 ml/min was eluted with a60-min
gradient to 0.35 M sodium phosphate, pH 7.4, 3.5 uM CaC12, 0.01% Tween-20. The elution
positions of other proteins are indicated by horizontal bars (A) . Gel filtration of 0.2-ml 30-fold
concentrated D10 supernatant onTSK-G 3000SW wasperformed as previously described (33)
(B). The elution positions of proteins of known molecular weight are marked by the arrows . In
both cases the absorbance at 280 nm was monitored (curved line) and aliquots from the 1-min
fractions were assayed for CSIF activity (shaded areas) .
tivity . CSIF activity was not reduced by mAbs specific for IL-2, IL-3, IL-4, and
IL-6 (10 ttg/ml), IL-5 (2 Wg/ml), and GM-CSF (20 jig/ml), or by polyclonal anti-
TGFa antibodies (50 jig/ml) . Several cytokines were also tested in the CSIF assay
and found to be inactive, either as agonists or antagonists . The synthesis of IFN-'y
was enhanced or inhibited by <11% by IL-1 (101 U/ml), IL-5 (2.4 ng/ml), IL-6 (25
ng/ml), or IL-7 (500 U/ml) . IFN-y synthesis was enhanced by IL-2 and IL-4 (Fig .
6), slightly enhanced by P40 (results not shown), and inhibited by TGF0 (Fig. 6) .
Experiments using recombinant cytokines and mAbs, as well as knowledge of its
biochemical properties and presence in Th2 but not Thl supernatants, distinguish
CSIFfrom many of theknown cytokines (Table III) . In general, we required at least
twononidentical properties before each cytokine wasconsidered distinct from CSIF.
According to these criteria, CSIF is not IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
GM-CSF, IFN--y, IT, TNF, TGFa, P40, or met-enkephalin, and is unlikely to be
soluble immune response suppressor (SIRS) (38) .
Discussion
Several linesof evidence show that antibody andDTH responses are often mutu-
ally exclusive (16-18, 39). If these responses are mainly due to Th2 and Thl cells,
respectively, this suggests thatThl and Th2 cells reciprocally inhibit the growth and
function of the other cell type. Some of the known mechanisms include the inhibi-
tion of growth of Th2 clones by IFN-y (19, 20), the inhibition of all IL-4 effects
on B cells by IFN--y (40), and the inhibition ofThl proliferation by a Th2-derived
factor (21) . Although the activity in the last study was identified as an autocrineFIORENTINO ET AL.
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TABLE III
Evidencefor Nonidentity of CSIF with Known Cytokines
growth inhibitor for Th cells, the results need to be reinterpreted in light of recent
information (1, 3, 5). TheTh2-derived growth inhibitory activity inhibitedthegrowth
of a Thl clone "1,000-fold more effectively than D10 growth (21), but it appears
to be distinct from CSIF since the two activities have different apparent molecular
masses, and ppCSIF does not inhibit proliferation of Thl clones.
In addition to IFN-yandthe D10-derived proliferation inhibitor, the CSIF identified
in this studycouldbe another ofthe crossinhibitory regulators ofThl andTh2 cells.
Thl function should be inhibited by CSIF, since IFN-y is an important mediator
of several Thl functions (7, 12, 41). There may also be an indirect enhancement
of Th2 growth, since the decrease in IFN-y levels should reduce inhibitory effects
on Th2 growth (19, 20). CSIF inhibition of IL-2 but not IL-4 synthesis may also
slightly reduce the relative growth rates of Thl cells, since Th2 cells respond better
than Thl cells to the proliferative effects of IL-4 (3). We have suggested previously
(3) that these crossinhibitory cytokine effects may be important early in immune
responses, whereas the production of specific Ig isotypes may counterbalance this
effect later in the response.
CSIF could also have a more subtle role in the regulation of immune responses.
In vitro, Thl clones are often very poor B cell helpers (8, 9), unless the cytokine
levels are adjusted by decreasing IFN-y and increasing IL-2 levels (7). Since CSIF
inhibits IFN-y production, often more effectively than IL-2 production, and freshly
isolated Thl clones tend to produce more IL-2 than long-termThl clones (2), CSIF
may modify thefunctionsofThl cellsso that they become more effectiveBcell helpers.
If true, this effect would only be seen in responses in which at least some Th2 cells
were activated. This mayexplain the apparently contradictory observations that Thl
cells can be good B cell helpers under some circumstances, but that a strong DTH
response (presumably due to strong Thl activation) is often unaccompanied by
significant antibody synthesis.
CSIF appears to selectively inhibit Thl cytokine synthesis, rather than generally
Cytokine
Present in
Th2 sup
Absent in
Thl sup
Ab blocks
CSIF activity
Cytokine has
CSIF activity
Biochemically
similar to CSIF
IL-1 No Yes - No No: separates by size
IL-2 No No No No -
IL-3 Yes No No - No: separates on HPHT
IL-4 Yes Yes No No No: separates on HPHT, size
IL-5 Yes Yes No No -
IL-6 Yes Yes No No No: separates by size
IL-7 - - - No No: not acid labile
GM-CSF Yes No No - No: not acid labile
IFN No No - - -
LT No No - - -
TNF Yes No - - No: not acid labile
TGF-0 - - No Yes (partial) No: not acid labile
P40 Yes - - No No: not acid labile
Met-enk Yes No - - No: separates by size
SIRS - - - - No: separates by size2092
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inhibit cell growth or viability. CSIF treatment did not reduce the levels of-y-actin
mRNA, nor did it inhibit proliferation in response to exogenous IL-2. Although
IL-2 enhances IFN--yproduction (42, andFig. 6), andCSIFoften inhibits IL-2 produc-
tion, the results in Fig. 6 also show that CSIF exerts its effect in either the presence
orabsence ofIL-2. This indicatesthatCSIF does not inhibitIFN-'y synthesis simply
by inhibiting IL-2 production. Although TGF/3 also inhibits IFN-y synthesis (43,
andFig. 6), CSIFwas able to inhibit IFN--y synthesismore effectively than saturating
amounts ofTGF0. This indicates that CSIF does not act only by inducing TGF0.
The action of CSIF on Thl cytokine synthesis may be indirect, since (a) CSIF
inhibits IFN--y synthesis in response to antigen plus APC but not Con A; (b) IFN-.y
synthesis is inhibited only at later times after stimulation; and (c) the volume ofthe
assay iscriticallyimportantto thedegree ofinhibitionobtained. Twopossible mech-
anisms are the induction by CSIF of an effector molecule synthesized by a cell in
the APC population, or the modification of CSIF to an active form by the APC
population. Preliminaryexperiments(unpublished data)showthatAPC pretreated
with CSIF are only marginally reduced in their ability to subsequently induce Thl
cells to produce IFN-.y. This indicates that, ifCSFacts primarily on the APC popu-
lation, the effect is mostly reversible, or requires the presence of T cells.
Analysis of IFN--y mRNA levels showed that the effect of CSIF is mediated at
the mRNA level, in agreement with intracellular protein measurements. Possible
mechanisms include reduction oftranscription, accelerated degradation, or altered
mRNA processing. IFN--y mRNA levels were slightly reduced at 8 h, and strongly
reduced by 12 h, consistent with IFN-,y secretion datashowing thatCSIF inhibition
is detected only at late times. The delayed inhibition ofIFN-,y production may also
explain why saturating CSIF never completely inhibits cytokine synthesis; the re-
sidual cytokine levels may represent the amounts of cytokines synthesized at early
times after stimulation.
Althoughthe Thl and Th2 phenotypes aredisplayed bythe majorityoflong-term
mouse Th clones, other cytokine secretion patterns exist among normal Th cells
and short-term clones (2, 13, 20, and Street, N. E., J. H. Schumacher, T. A. T.
Fong, H. Bass, D. F. Fiorentino, J. A. Leverah, and T. R. Mosmann, manuscript
submitted for publication). These other phenotypes may be precursors ofThl and
Th2 cells, and the details of the functions of such precursors are not yet known.
It will be important to assess CSIF production and effects in these other Th types,
particularly in cells secreting both Thl and Th2 cytokines.
The interpretation ofthe role ofCSIF is complicated by the fact that Th2 cells
also produce IL-4, which partially counteracts the effects of CSIF. This situation
is analogoustotheproduction ofIL-2 and IFN-,ybyThl cells, sincethesetwocytokines
have opposing effects on Th2 cells (19, 20). It is possible that these pairs ofcytokines
are produced in different ratios under different conditions, or that the local clear-
ance rates of each cytokine are very different, leadingto temporal differences in the
effects observed. Resolution ofthesequestionsawaits improved methods for detecting
and manipulating cytokine levels in vivo.
Summary
A cytokine synthesis inhibitory factor (CSIF) issecreted byTh2 clones in response
to ConA or antigenstimulation, but is absent in supernatants from Con A-inducedFIORENTINO ET AL.
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Thl clones. CSIF can inhibit the production ofIL-2, IL-3, lymphotoxin (LT)/TNF,
IFN--y, and granulocyte-macrophage CSF (GM-CSF) by Thl cells responding to
antigen and APC, but Th2 cytokine synthesis is not significantly affected. Trans-
forming growth factorS (TGFj3) also inhibits IFN-yproduction, although less effec-
tively than CSIF, whereas IL-2 and IL-4 partially antagonize the activity of CSIF
CSIF inhibition of cytokine synthesis is not complete, since early cytokine synthesis
(before 8 h) is not significantly affected, whereas later synthesis is strongly inhibited.
In the presence ofCSIF, IFN-y mRNA levels are reduced slightly at 8, and strongly
at 12 h after stimulation. Inhibition of cytokine expression by CSIF is not due to
a general reduction in Thl cell viability, since actin mRNA levels were not reduced,
and proliferation of antigen-stimulated cells in response to IL-2, was unaffected.
Biochemical characterization, mAbs, and recombinant or purified cytokines showed
that CSIF is distinct from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IFN-y, GM-
CSF, TGF,3, TNF, IT, and P40. The potential role of CSIF in crossregulation of
Thl and Th2 responses is discussed.
We thankJ. Abrams, R. Coffman, M. Howard, R. Kastelein, F Lee, M. Palladino,J. Schreurs,
J. van Snick, and G. Zurawski for providing valuable cytokine and antibody reagents. We
thankJ. Schumacher for providing technical advice and F Vega for synthesizing oligonucle-
otides.
Note added in proof The identity of CSIF as a novel cytokine has recently been confirmed by
the isolation of a cDNA clone that expresses CSIF activity when transfected into COS cells
(Moore, K. W. et al., manuscript in preparation). mAbs specific for CSIF react with both
the recombinant protein and the 1310-derived factor (Mosmann, T. R. et al., manuscript in
preparation). The sequence ofthe cDNA clone is different from all previously known cytokines.
At the time of submission of this cDNA clone sequence for publication, we will request the
Nomenclature Committee of the International Union of Immunological Societies to assign
an IL designation for this factor.
Receivedfor publication 19June 1989 and in revisedform 28 August 1989.
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